Quantitative
AL
ATTR
Cardiac amyloidosis
Perugini
SPECT
imaging
quantification
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
08
07
2021
accepted:
06
02
2022
pubmed:
14
5
2022
medline:
8
3
2023
entrez:
13
5
2022
Statut:
ppublish
Résumé
Transthyretin (ATTR) amyloidosis is responsible for the majority of cardiac amyloidosis (CA) cases and can be reliably diagnosed with bone scintigraphy and the visual Perugini score. We aimed to implement a quantification method of cardiac amyloid deposits in patients with suspected cardiac amyloidosis and to compare performance to visual scoring. 136 patients received Forty-five patients were diagnosed with CA. A strong relationship between cardiac SUVmax and Perugini score was found (Spearman r 0.75, p < 0.0001). Additionally, tracer uptake in bone decreased with increasing cardiac SUVmax and Perugini score (p < 0.0001). ROC analysis revealed good performance of the SUVmax for the detection of ATTR-CA with AUC of 0.96 ± 0.02 (p < 0.0001) with sensitivity 98.7% and specificity 87.2%. We demonstrate an accessible and accurate quantitative SPECT approach in CA. Quantitative assessment of the cardiac tracer uptake may improve diagnostic accuracy and risk classification. This method may enable monitoring and assessment of therapy response in patients with ATTR amyloidosis.
Identifiants
pubmed: 35562639
doi: 10.1007/s12350-022-02960-3
pii: 10.1007/s12350-022-02960-3
pmc: PMC9984322
doi:
Substances chimiques
Prealbumin
0
Technetium-99
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101-111Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
Circulation. 2016 Jun 14;133(24):2404-12
pubmed: 27143678
Eur Heart J. 2015 Oct 7;36(38):2585-94
pubmed: 26224076
Eur J Hybrid Imaging. 2017;1(1):2
pubmed: 29782587
J Am Coll Cardiol. 2016 Sep 6;68(10):1014-20
pubmed: 27585505
Circ Cardiovasc Imaging. 2013 Mar 1;6(2):195-201
pubmed: 23400849
J Nucl Cardiol. 2021 Feb;28(1):90-99
pubmed: 30767162
J Nucl Med. 2021 May 10;62(5):716-722
pubmed: 32887756
J Card Fail. 2019 Nov;25(11):e1-e39
pubmed: 31473268
Eur Heart J. 2021 Apr 21;42(16):1554-1568
pubmed: 33825853
Blood. 2013 Apr 25;121(17):3420-7
pubmed: 23479568
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
J Clin Oncol. 2012 Dec 20;30(36):4541-9
pubmed: 23091105
Circ Heart Fail. 2019 Sep;12(9):e006075
pubmed: 31480867
J Nucl Cardiol. 2020 Oct;27(5):1456-1463
pubmed: 31538322
Blood. 2020 Dec 3;136(23):2620-2627
pubmed: 33270858
JACC Cardiovasc Imaging. 2017 May;10(5):601-603
pubmed: 27424245
Eur Heart J. 2016 Jun 14;37(23):1826-34
pubmed: 26537620
Amyloid. 2018 Sep;25(3):203-210
pubmed: 30486686
JACC Cardiovasc Imaging. 2020 Jun;13(6):1353-1363
pubmed: 32498921
J Nucl Cardiol. 2016 Dec;23(6):1355-1363
pubmed: 26453570
J Xray Sci Technol. 2018;26(6):895-908
pubmed: 30103368
Medicine (Baltimore). 2019 Jan;98(2):e14022
pubmed: 30633193
Amyloid. 2014 Mar;21(1):35-44
pubmed: 24455993
JAMA Cardiol. 2016 Nov 1;1(8):880-889
pubmed: 27557400
Ann Nucl Med. 2012 Oct;26(8):634-43
pubmed: 22777859
Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S17-25
pubmed: 24037503
J Am Coll Cardiol. 2005 Sep 20;46(6):1076-84
pubmed: 16168294